Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation

Myung-Gyu Kim, Yoon Jung Kim, Hyuk Yong Kwon, Hayne Cho Park, Tai Yeon Koo, Jong Cheol Jeong, Hee Jung Jeon, Miyeun Han, Curie Ahn, Jaeseok Yang

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Aim: Chronic antibody-mediated rejection (CAMR) in renal transplant patients has poor allograft outcomes. However, treatment strategy has not been established yet. Herein, we present short-term outcomes of combination therapy for CAMR. Methods: We identified nine patients with CAMR or suspicious CAMR who were treated with antihumoral therapy from 2010 to 2011 and analyzed their medical records retrospectively. Results: Five patients had CAMR, and four patients had suspicious CAMR. Severe transplant glomerulopathy (TG) was observed in seven patients. The estimated glomerular filtration rate (eGFR) was decreased in all patients before treatment. We used three different treatment regimens: (i) high-dose intravenous immunoglobulin (IVIG) and rituximab; (ii) high-dose IVIG, rituximab, and bortezomib; and (iii) plasmapheresis with low-dose IVIG, rituximab and bortezomib. After treatment with one of these three regimens, graft function improved or stabilized in six patients, whereas three patients showed further deterioration of eGFR. The third regimen suppressed deterioration of renal function in all patients. Most patients showed no progression of proteinuria. Infectious complications due to Pneumocystis jirovecii pneumonia and herpes zoster occurred in two patients. Conclusion: Combination therapy for CAMR might be effective, even in patients with relatively late-stage CAMR.

Original languageEnglish
Pages (from-to)820-826
Number of pages7
JournalNephrology
Volume18
Issue number12
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Kidney Transplantation
Antibodies
Intravenous Immunoglobulins
Therapeutics
Glomerular Filtration Rate
Transplants
Kidney
Pneumocystis carinii
Pneumocystis Pneumonia
Plasmapheresis
Herpes Zoster
Proteinuria
Medical Records
Allografts

Keywords

  • bortezomib
  • chronic antibody-mediated rejection
  • immunoglobulin
  • plasmapheresis
  • rituximab

ASJC Scopus subject areas

  • Nephrology

Cite this

Kim, M-G., Kim, Y. J., Kwon, H. Y., Park, H. C., Koo, T. Y., Jeong, J. C., ... Yang, J. (2013). Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation. Nephrology, 18(12), 820-826. https://doi.org/10.1111/nep.12157

Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation. / Kim, Myung-Gyu; Kim, Yoon Jung; Kwon, Hyuk Yong; Park, Hayne Cho; Koo, Tai Yeon; Jeong, Jong Cheol; Jeon, Hee Jung; Han, Miyeun; Ahn, Curie; Yang, Jaeseok.

In: Nephrology, Vol. 18, No. 12, 01.01.2013, p. 820-826.

Research output: Contribution to journalArticle

Kim, M-G, Kim, YJ, Kwon, HY, Park, HC, Koo, TY, Jeong, JC, Jeon, HJ, Han, M, Ahn, C & Yang, J 2013, 'Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation', Nephrology, vol. 18, no. 12, pp. 820-826. https://doi.org/10.1111/nep.12157
Kim, Myung-Gyu ; Kim, Yoon Jung ; Kwon, Hyuk Yong ; Park, Hayne Cho ; Koo, Tai Yeon ; Jeong, Jong Cheol ; Jeon, Hee Jung ; Han, Miyeun ; Ahn, Curie ; Yang, Jaeseok. / Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation. In: Nephrology. 2013 ; Vol. 18, No. 12. pp. 820-826.
@article{a2fd6af2e7d1446ba29606b66f5d8148,
title = "Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation",
abstract = "Aim: Chronic antibody-mediated rejection (CAMR) in renal transplant patients has poor allograft outcomes. However, treatment strategy has not been established yet. Herein, we present short-term outcomes of combination therapy for CAMR. Methods: We identified nine patients with CAMR or suspicious CAMR who were treated with antihumoral therapy from 2010 to 2011 and analyzed their medical records retrospectively. Results: Five patients had CAMR, and four patients had suspicious CAMR. Severe transplant glomerulopathy (TG) was observed in seven patients. The estimated glomerular filtration rate (eGFR) was decreased in all patients before treatment. We used three different treatment regimens: (i) high-dose intravenous immunoglobulin (IVIG) and rituximab; (ii) high-dose IVIG, rituximab, and bortezomib; and (iii) plasmapheresis with low-dose IVIG, rituximab and bortezomib. After treatment with one of these three regimens, graft function improved or stabilized in six patients, whereas three patients showed further deterioration of eGFR. The third regimen suppressed deterioration of renal function in all patients. Most patients showed no progression of proteinuria. Infectious complications due to Pneumocystis jirovecii pneumonia and herpes zoster occurred in two patients. Conclusion: Combination therapy for CAMR might be effective, even in patients with relatively late-stage CAMR.",
keywords = "bortezomib, chronic antibody-mediated rejection, immunoglobulin, plasmapheresis, rituximab",
author = "Myung-Gyu Kim and Kim, {Yoon Jung} and Kwon, {Hyuk Yong} and Park, {Hayne Cho} and Koo, {Tai Yeon} and Jeong, {Jong Cheol} and Jeon, {Hee Jung} and Miyeun Han and Curie Ahn and Jaeseok Yang",
year = "2013",
month = "1",
day = "1",
doi = "10.1111/nep.12157",
language = "English",
volume = "18",
pages = "820--826",
journal = "Nephrology",
issn = "1320-5358",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation

AU - Kim, Myung-Gyu

AU - Kim, Yoon Jung

AU - Kwon, Hyuk Yong

AU - Park, Hayne Cho

AU - Koo, Tai Yeon

AU - Jeong, Jong Cheol

AU - Jeon, Hee Jung

AU - Han, Miyeun

AU - Ahn, Curie

AU - Yang, Jaeseok

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Aim: Chronic antibody-mediated rejection (CAMR) in renal transplant patients has poor allograft outcomes. However, treatment strategy has not been established yet. Herein, we present short-term outcomes of combination therapy for CAMR. Methods: We identified nine patients with CAMR or suspicious CAMR who were treated with antihumoral therapy from 2010 to 2011 and analyzed their medical records retrospectively. Results: Five patients had CAMR, and four patients had suspicious CAMR. Severe transplant glomerulopathy (TG) was observed in seven patients. The estimated glomerular filtration rate (eGFR) was decreased in all patients before treatment. We used three different treatment regimens: (i) high-dose intravenous immunoglobulin (IVIG) and rituximab; (ii) high-dose IVIG, rituximab, and bortezomib; and (iii) plasmapheresis with low-dose IVIG, rituximab and bortezomib. After treatment with one of these three regimens, graft function improved or stabilized in six patients, whereas three patients showed further deterioration of eGFR. The third regimen suppressed deterioration of renal function in all patients. Most patients showed no progression of proteinuria. Infectious complications due to Pneumocystis jirovecii pneumonia and herpes zoster occurred in two patients. Conclusion: Combination therapy for CAMR might be effective, even in patients with relatively late-stage CAMR.

AB - Aim: Chronic antibody-mediated rejection (CAMR) in renal transplant patients has poor allograft outcomes. However, treatment strategy has not been established yet. Herein, we present short-term outcomes of combination therapy for CAMR. Methods: We identified nine patients with CAMR or suspicious CAMR who were treated with antihumoral therapy from 2010 to 2011 and analyzed their medical records retrospectively. Results: Five patients had CAMR, and four patients had suspicious CAMR. Severe transplant glomerulopathy (TG) was observed in seven patients. The estimated glomerular filtration rate (eGFR) was decreased in all patients before treatment. We used three different treatment regimens: (i) high-dose intravenous immunoglobulin (IVIG) and rituximab; (ii) high-dose IVIG, rituximab, and bortezomib; and (iii) plasmapheresis with low-dose IVIG, rituximab and bortezomib. After treatment with one of these three regimens, graft function improved or stabilized in six patients, whereas three patients showed further deterioration of eGFR. The third regimen suppressed deterioration of renal function in all patients. Most patients showed no progression of proteinuria. Infectious complications due to Pneumocystis jirovecii pneumonia and herpes zoster occurred in two patients. Conclusion: Combination therapy for CAMR might be effective, even in patients with relatively late-stage CAMR.

KW - bortezomib

KW - chronic antibody-mediated rejection

KW - immunoglobulin

KW - plasmapheresis

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=84888862075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888862075&partnerID=8YFLogxK

U2 - 10.1111/nep.12157

DO - 10.1111/nep.12157

M3 - Article

C2 - 24033843

AN - SCOPUS:84888862075

VL - 18

SP - 820

EP - 826

JO - Nephrology

JF - Nephrology

SN - 1320-5358

IS - 12

ER -